Status:
COMPLETED
Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered To Infants In Korea
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Pneumococcal Vaccine
Eligibility:
All Genders
42-98 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate vaccine (7vPnC)...
Eligibility Criteria
Inclusion
- Healthy 2-month-old-infants (42 to 98 days)
- Available for the entire study period (14 months)
Exclusion
- Previous vaccine with pneumococcal, diptheria, tetanus, pertussis, polio or Hib vaccine
- A previous severe reaction to any vaccine or vaccine-related component
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00689351
Start Date
June 1 2008
End Date
December 1 2009
Last Update
June 28 2011
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Incheon, Bupyeong-gu, South Korea, 400-711
2
Pfizer Investigational Site
Seoul, Jongno-gu, South Korea, 110-744
3
Pfizer Investigational Site
Incheon, Jung-gu, South Korea, 400-711
4
Pfizer Investigational Site
Kyunggi, Koyang, South Korea, 412-270